[Cystatin C as a marker of glomerular filtration rate in patients with ovarian cancer].

UNLABELLED: Cystatin C, a cysteine protease inhibitor, has been recommended as a new marker of glomerular filtration rate (GFR). THE AIM OF STUDY We investigated significance of cystatin C in assessment of GFR and its influence on overall survival (OS) in patients with ovarian cancer (OC).

MATERIAL AND METHODS: We prospectively included consecutive patients with OC, who after surgery were qualified to first line chemotherapy according to the following protocol: cisplatin 75 mg/m2 and 24-hour infusion of paclitaxel 135 mg/m2 every three weeks. We assessed: serum levels of creatinine (Cr), cystatin C (Cys C), creatinine clearance (ClCr) calculated from 24-hour urine collection, GFR estimated according to Cocroft-Gault (CG) and Modification Diet of Renal Disease (MDRD) formulas.

RESULTS: Age median of 37 patients enrolled into this study was 54 years (range from 28 to 68). We noted correlation between cystatin C and CrCl (R Spearman= -0.36; p = 0.03). We did not state any correlation between Cys C and another markers of GFR as: serum creatinine, CG, MDRD. However, we observed correlation between Cys C and measured tumor mass seeing in spiral CT-scan (diameter more than 1 cm) after surgery (R Spearman = 0.4; p = 0.01) and serum level of marker CA 125 (R Spearman= 0.4; p = 0.03). We didn't find any statistical correlation between values of serum Cys C (using median's as cutoff values) in overall survival of our patients (log-rank test, p = 0.9).

CONCLUSIONS: Serum cystatin C level in patient with ovarian cancer is both the poor marker of GFR and has not prognostic value in the course of cancer after surgery with further primary chemotherapy. The explanation of this phenomenon could rely on the presence of residual ovarian cancer.